Global Infertility Drugs 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01250349

Publication Date:

January 17, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Infertility Drugs market size is predicted to grow from US$ 5608 million in 2025 to US$ 7777 million in 2031; it is expected to grow at a CAGR of 5.6% from 2025 to 2031.
Infertility Drugs are drugs which enhance reproductive fertility. For women, Infertility Drugs is used to stimulate follicle development of the ovary. Agents that enhance ovarian activity can be classified as either Gonadotropin releasing hormone, Estrogen antagonists or Gonadotropins.
Global Infertility Drugs key players include LIVZON, Merck, Abbott, Ferring, etc. Global top four manufacturers hold a share about 45%.
North America is the largest market, with a share about 45%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Gonadotropins is the largest segment, with a share nearly 80%. And in terms of application, the largest application is Female, followed by Male.
The 鈥淚nfertility Drugs Industry Forecast鈥� looks at past sales and reviews total world Infertility Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Infertility Drugs sales for 2025 through 2031. With Infertility Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Infertility Drugs industry.
This Insight Report provides a comprehensive analysis of the global Infertility Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Infertility Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Infertility Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Infertility Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Infertility Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Infertility Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Gonadotropins
Anti-Estrogens
Other
Segmentation by Application:
Male
Female
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Ferring
MSD
LIVZON
Abbott
Bayer Zydus Pharma

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Infertility Drugs 麻豆原创 Size (2020-2031)
2.1.2 Infertility Drugs 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Infertility Drugs by Country/Region (2020, 2024 & 2031)
2.2 Infertility Drugs Segment by Type
2.2.1 Gonadotropins
2.2.2 Anti-Estrogens
2.2.3 Other
2.3 Infertility Drugs 麻豆原创 Size by Type
2.3.1 Infertility Drugs 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Infertility Drugs 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Infertility Drugs Segment by Application
2.4.1 Male
2.4.2 Female
2.5 Infertility Drugs 麻豆原创 Size by Application
2.5.1 Infertility Drugs 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Infertility Drugs 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Infertility Drugs 麻豆原创 Size by Player
3.1 Infertility Drugs 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Infertility Drugs Revenue by Player (2020-2025)
3.1.2 Global Infertility Drugs Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Infertility Drugs Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Infertility Drugs by Region
4.1 Infertility Drugs 麻豆原创 Size by Region (2020-2025)
4.2 Global Infertility Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Infertility Drugs 麻豆原创 Size Growth (2020-2025)
4.4 APAC Infertility Drugs 麻豆原创 Size Growth (2020-2025)
4.5 Europe Infertility Drugs 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Infertility Drugs 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Infertility Drugs 麻豆原创 Size by Country (2020-2025)
5.2 Americas Infertility Drugs 麻豆原创 Size by Type (2020-2025)
5.3 Americas Infertility Drugs 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Infertility Drugs 麻豆原创 Size by Region (2020-2025)
6.2 APAC Infertility Drugs 麻豆原创 Size by Type (2020-2025)
6.3 APAC Infertility Drugs 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Infertility Drugs 麻豆原创 Size by Country (2020-2025)
7.2 Europe Infertility Drugs 麻豆原创 Size by Type (2020-2025)
7.3 Europe Infertility Drugs 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Infertility Drugs by Region (2020-2025)
8.2 Middle East & Africa Infertility Drugs 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Infertility Drugs 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Infertility Drugs 麻豆原创 Forecast
10.1 Global Infertility Drugs Forecast by Region (2026-2031)
10.1.1 Global Infertility Drugs Forecast by Region (2026-2031)
10.1.2 Americas Infertility Drugs Forecast
10.1.3 APAC Infertility Drugs Forecast
10.1.4 Europe Infertility Drugs Forecast
10.1.5 Middle East & Africa Infertility Drugs Forecast
10.2 Americas Infertility Drugs Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Infertility Drugs Forecast
10.2.2 Canada 麻豆原创 Infertility Drugs Forecast
10.2.3 Mexico 麻豆原创 Infertility Drugs Forecast
10.2.4 Brazil 麻豆原创 Infertility Drugs Forecast
10.3 APAC Infertility Drugs Forecast by Region (2026-2031)
10.3.1 China Infertility Drugs 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Infertility Drugs Forecast
10.3.3 Korea 麻豆原创 Infertility Drugs Forecast
10.3.4 Southeast Asia 麻豆原创 Infertility Drugs Forecast
10.3.5 India 麻豆原创 Infertility Drugs Forecast
10.3.6 Australia 麻豆原创 Infertility Drugs Forecast
10.4 Europe Infertility Drugs Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Infertility Drugs Forecast
10.4.2 France 麻豆原创 Infertility Drugs Forecast
10.4.3 UK 麻豆原创 Infertility Drugs Forecast
10.4.4 Italy 麻豆原创 Infertility Drugs Forecast
10.4.5 Russia 麻豆原创 Infertility Drugs Forecast
10.5 Middle East & Africa Infertility Drugs Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Infertility Drugs Forecast
10.5.2 South Africa 麻豆原创 Infertility Drugs Forecast
10.5.3 Israel 麻豆原创 Infertility Drugs Forecast
10.5.4 Turkey 麻豆原创 Infertility Drugs Forecast
10.6 Global Infertility Drugs Forecast by Type (2026-2031)
10.7 Global Infertility Drugs Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Infertility Drugs Forecast
11 Key Players Analysis
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Infertility Drugs Product Offered
11.1.3 Merck Infertility Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Merck Main Business Overview
11.1.5 Merck Latest Developments
11.2 Ferring
11.2.1 Ferring Company Information
11.2.2 Ferring Infertility Drugs Product Offered
11.2.3 Ferring Infertility Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Ferring Main Business Overview
11.2.5 Ferring Latest Developments
11.3 MSD
11.3.1 MSD Company Information
11.3.2 MSD Infertility Drugs Product Offered
11.3.3 MSD Infertility Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 MSD Main Business Overview
11.3.5 MSD Latest Developments
11.4 LIVZON
11.4.1 LIVZON Company Information
11.4.2 LIVZON Infertility Drugs Product Offered
11.4.3 LIVZON Infertility Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 LIVZON Main Business Overview
11.4.5 LIVZON Latest Developments
11.5 Abbott
11.5.1 Abbott Company Information
11.5.2 Abbott Infertility Drugs Product Offered
11.5.3 Abbott Infertility Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Abbott Main Business Overview
11.5.5 Abbott Latest Developments
11.6 Bayer Zydus Pharma
11.6.1 Bayer Zydus Pharma Company Information
11.6.2 Bayer Zydus Pharma Infertility Drugs Product Offered
11.6.3 Bayer Zydus Pharma Infertility Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Bayer Zydus Pharma Main Business Overview
11.6.5 Bayer Zydus Pharma Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.